| Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. Co.'s allogeneic cellular immunotherapy pipeline includes: ProTmune, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft. We show 33 historical shares outstanding datapoints in our coverage of FATE's shares outstanding history.|
Understanding the changing numbers of FATE shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like FATE versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching FATE by allowing them to research FATE shares outstanding history
as well as any other stock in our coverage universe.